Ameriprise’s Adial Pharmaceuticals Warrant ADILW Stock Holding History

Ameriprise’s Portfolio ADILW Stock Details ADILW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-35,000	Closed	-$200	–	4021
2023 Q2	$200	Hold	35,000	–	–	﹤0.01%	3902
2023 Q1	$1.3K	Hold	35,000	–	–	﹤0.01%	3932
2022 Q4	$1K	Hold	35,000	–	–	﹤0.01%	3950
2022 Q3	$3K	Buy	35,000 +20,000	+133%	+$2K	﹤0.01%	3947
2022 Q2	$4K	Hold	15,000	–	–	﹤0.01%	3877
2022 Q1	$7K	Hold	15,000	–	–	﹤0.01%	3922
2021 Q4	$10K	Hold	15,000	–	–	﹤0.01%	3941
2021 Q3	$14K	Hold	15,000	–	–	﹤0.01%	3841
2021 Q2	$11K	Buy	+15,000	New	+$10.1K	﹤0.01%	3877

Ameriprise's ADILW Position: Q3 2023 in Review

Ameriprise sold out of Adial Pharmaceuticals Warrant (ADILW) in Q3 2023, closing a stake of 35,000 shares — an estimated $200 sold.

Ameriprise first reported a position in ADILW in Q2 2021 and held it in 9 quarters. The position peaked at $14K in Q3 2021. 0 funds tracked by Wall St. Rank hold ADILW as of Q3 2023.

Ameriprise reported no remaining Adial Pharmaceuticals Warrant position as of Q3 2023 after selling out during the quarter.
Ameriprise sold 35,000 Adial Pharmaceuticals Warrant shares in Q3 2023, an estimated $200.
Ameriprise first reported a position in Adial Pharmaceuticals Warrant in Q2 2021 and held it in 9 quarters.
Ameriprise's Adial Pharmaceuticals Warrant position peaked at $14K in Q3 2021.
0 funds tracked by Wall St. Rank held Adial Pharmaceuticals Warrant as of Q3 2023.

Based on Ameriprise's 13F filing for Q3 2023, filed 14 Nov 2023.